December 2022

Mise en œuvre du système de notation OMERACT pour l'imagerie par résonance magnétique du rhumatisme psoriasique dans une étude randomisée de phase IIb de l'abatacept dans le rhumatisme psoriasique

Rheumatology (Oxford) 2022 doi: 10.1093/rheumatology/keac073

In this study abatacept 30/10 mg/kg and 10 mg/kg doses were associated with greater improvements from baseline in MRI detected synovitis and tenosynovitis, respectively, compared with placebo, confirming the clinical outcomes. Indeed, inflammatory components demonstrated the greatest change from baseline.

Keywords:

Évaluation de la TEV, du MACE et des infections graves chez les patients PR traités par le baricitinib par rapport au TNFi : Une étude multi-bases de données de patients en soins de routine, utilisant des registres de maladies et bases de données des réclamations

Rheumatol Ther. 2022. Epub ahead of print doi: 10.1007/s40744-022-00505-1

Salinas, et al. evaluate baricitinib safety with respect to VTE, MACE, and serious infection relative to TNFi in patients with RA, in routine care and observe an increased risk of VTE in patients taking baricitinib, compared to TNFi.

Keywords:

October 2022

Performance comparative des mesures composites issues de deux essais cliniques de phase III sur l'Ixekizumab dans le rhumatisme psoriasique

RMD Open. 2022 doi: 10.1136/rmdopen-2022-002457

In this latest investigation into ixekizumab more patients achieved targets assessed by mCPDAI and DAPSA than with other composites. This study assess’ the concordance and variability in performance of the composite measures in patients with PsA, as well as to provide greater granularity to the frequency and severity of residual symptoms in patients who achieve treatment targets.

Keywords:

July 2022

L'activité initiale de la maladie permet de prédire l'atteinte des objectifs thérapeutiques cDAPSA avec Apremilast : Résultats de phase III chez des patients atteints de rhumatisme psoriasique et DMARD-naïfs

J Rheumatol. 2022 doi: 10.3899/jrheum.210906

Baseline disease activity, as measured by cDAPSA, predicts the achievement of treatment targets in DMARD-naïve patients post- apremilast treatment. To come to this conclusion Mease, et al.  analysed data from the PALACE 4 clinical trial which investigated apremilast in DMARD-naïve patients. 175 patients receiving 30mg apremilast from baseline with cDAPSA data available, were analysed.

Keywords:

Efficacité des inhibiteurs du TNF, de l'abatacept, des inhibiteurs de l'IL6 et des inhibiteurs de JAK chez 31 846 patients atteints de polyarthrite rhumatoïde dans 19 registres de la collaboration "JAK-pot"

Ann Rheum Dis. 2022 doi: 10.1136/annrheumdis-2022-222586

Observational study of data, from large international collective of registers, finds similar overall drug retention rates between RA treatment groups.

Keywords:

June 2022

Effet du sécukinumab sur les facteurs de risque cardiovasculaire traditionnels et les biomarqueurs inflammatoires : Analyses post-hoc de données regroupées pour trois indications

Rheumatol Ther 2022 Jun;9(3):935-955. Doi: 10.1007/s40744-022-00434-z

Merola et al., reported the effect of interleukin (IL)-17A inhibition with secukinumab on cardiovascular (CV) risk parameters in patients with psoriasis, psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA) over 1 year of treatment. This study evaluated data from 19 secukinumab related clinical trials in phase 3/4 in psoriasis, PsA, and axSpA.

Keywords:

May 2022

Réponses à l'Ixekizumab chez les hommes et les femmes atteints de rhumatisme psoriasique : Résultats de deux essais cliniques randomisés de phase 3

doi: 10.1007/s40744-022-00445-w

Eder, et al. sought to investigate the sex-based differences in treatment response between male and female PsA patients. They found that overall male patients had higher clinical response rates and greater improvements in the individual components of these measures.

Keywords:

Innocuité de l'Ixekizumab chez les patients atteints de rhumatisme psoriasique : Données de quatre essais cliniques avec plus de 2000 années-patients de traitement

doi: 10.1136/annrheumdis-2021-222027

This analysis aimed to report the safety profile of ixekizumab for the PsA SPIRIT programme. The overall safety profile and tolerability of ixekizumab are consistent with the previously known safety profile in patients with PsA.

Keywords:

Traitement de la spondyloarthrite axiale : une mise à jour

Nat Rev Rheumatol. 18, 205–216 (2022) 2022 doi: 10.1038/s41584-022-00761-z

In this review Danve and Deodhar report an update on modern axSpa treatment. They found that in the past two decades substantial progress in the diagnosis and management of axSpA has been witnessed. Whilst ASAS classification criteria have enabled earlier diagnosis the increased availability of novel therapies, evolving drug safety data and novel clinical trials have allowed clinicians to rethink the placement and timing of drugs in disease management.

Keywords:

February 2022

Effet des ajustements de dose sur l'efficacité et l'innocuité du tofacitinib chez les patients atteints de polyarthrite rhumatoïde : analyse post hoc d'une étude ouverte d'extension à long terme (ORAL Sequel)

Clin Rheumatol. 2022 Jan 1. Epub ahead of print doi: 10.1007/s10067-021-05908-z

Post-hoc analysis shows that dosing up from tofacitinib 5 to 10 mg BID is associated with improved efficacy for up to 12 months, versus staying on 5 mg BID, and dosing down from 10 to 5 mg BID is not generally associated with a significant loss of efficacy.Although clinical trials have generally shown no significant differences, in terms of efficacy and safety, when switching tofacitinib dose up or down, these per-protocol switches are not directly informative for clinical decision-making in dai...

Keywords: